N/A
N=73
Disposable Stress Urinary Incontinence Pessary Device Study
Stress Urinary Incontinence
Bottom Line
View on ClinicalTrials.gov: NCT03323723 ↗Enrolled (actual)
73
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Percentage Reduction of Mean Pad Weight Gain (g/hr) During Treatment Phase as Compared to Baseline Phase. — -47.4 percent change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- SUI Device (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Rinovum Women's Health, Inc.
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Reduction of Mean Pad Weight Gain (g/hr) During Treatment Phase as Compared to Baseline Phase. |
-47.4 | — |
| SECONDARY Change in Mean SUI Episodes During Treatment Phase as Compared to Baseline Phase |
-1.00 | — |
| SECONDARY Change in Quality of Life From Before Treatment Phase to After Treatment Phase |
-4.35 | — |
| SECONDARY Adverse Events and Labs Evaluation to Determine Safety of the Device |
40; 3 | — |
Summary
This study is an interventional, single arm, multi-center study. It will be conducted at sites in the northeastern United States. The protocol will be approved by Chesapeake IRB or applicable local IRBs. The sample size will consist of approximately 50 participants. Participants will undergo an initial control period in which preweighed pads will be worn for 7 consecutive days for 12 hours. This will be followed by device usage for 14 consecutive days where participants will wear both device and preweighed pads simultaneously. for 12 hours.
Eligibility Criteria
Inclusion Criteria
- • Provision of signed and dated informed consent form
- Literacy must be in English (able to read and understand Informed Consent)
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Female, aged >18
- Be in generally good heath as determined by the Investigator
- Have a physician diagnosis of SUI that occurred prior to or during the screening visit of this study
- Have a > 3-month history of experiencing > 3 episodes of SUI per week
- Be willing to use the investigational pessary device for the control of urinary incontinence
- Have experience with wearing a tampon
- The most recent Pap smear is normal within 36 months.
Exclusion Criteria
- • Is pregnant, or planning to become pregnant during the study
- Has been physician diagnosed with urge urinary incontinence or mixed urinary incontinence prior to or during the screening visit for this study
- Is post-partum within 3 months
- Has had an intrauterine device (IUD) placement of less than 6 months
- Has self-reported difficulty emptying her bladder;
- Has a history of Toxic Shock Syndrome (TSS) or symptoms consistent with TSS;
- Has experienced difficulty inserting or wearing an intra-vaginal device, including a tampon;
- Has had vaginal surgery, perineal surgery, uterine surgery, or abortion (spontaneous or induced) within the past 3 months;
- Has any Screening laboratory value outside the laboratory reference range considered clinically significant by the Investigator which could impact the safety of the participant or the outcome of the study
- Has an active urinary tract infection or vaginal infection requiring treatment
- If for any reason, the Investigator decides that the participant should not participate in the study.
- Class III Obesity (BMI> 40.0 kg/m2)
- Advanced prolapse
- Fit assessment is not successful during screening visit
Data sourced from ClinicalTrials.gov (NCT03323723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.